PET-CT Imaging Using FDG-labeled Human Erythrocytes in Breast Cancer Patient

Summary

This is a single arm, phase 0 study to evaluate the safety and efficacy of PET-CT scans with FDG-labeled RBC in patients with breast cancer. Cardiac ejection fraction can be calculated and monitored in breast cancer patients during chemotherapy using a FDG-RBC PET-CT scan. The purpose of this study is to determine if calculated cardiac ejection fraction shows high concordance with results from echocardiography.

Timeline

Start

2020-12

Primary completion

2021-12

Completion

2022-12

Drugs

Indications